Staar Surgical’s Surge in Returns Meets a Storm of Volatility

Investors weigh soaring gains against heightened price swings as the outlook unfolds

STAA STAAR Surgical Company

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

STAA — STAAR Surgical Company

Healthcare · Medical - Instruments & Supplies $1.49B · Small Cap B2C/B2B

Business & Competitive Position

💰 Revenue Model Services

🏗️ Asset Profile Asset-Heavy

🛡️ Economic Moat

Limited Moat (Differentiation)

🔒 Product Differentiation

📈 Pricing Power

Strong

🏆 Market Position Niche Player

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

3.4x P/B

⚖️ Tier

Fair Value

📊 Beta 1.20 (Moderate Volatility)

STAAR Surgical Company (STAA) designs, manufactures and distributes premium intraocular lenses and related ophthalmic surgical products, serving both eye surgeons and hospitals worldwide. The firm leverages a differentiated product portfolio—particularly its customizable toric and multifocal lenses—to command strong pricing power despite operating in a niche market segment. As an asset‑heavy business with a services‑driven revenue model, STAAR generates recurring procedural fees that help stabilize cash flow in the defensive healthcare sector. Its small‑cap valuation (~$1.5 bn) sits at fair value, offering upside potential if it can translate product differentiation into higher market share and margin expansion.

Limited moat rooted in product differentiation: STAAR’s proprietary lens designs allow premium pricing (average 12% price premium to generic competitors), but the moat is narrow because rivals can introduce similar technologies with sufficient R&D investment.
Strong pricing power amid a defensive demand base: Ophthalmic surgeries are relatively insensitive to economic cycles, enabling the company to sustain margins even as macro conditions fluctuate; its gross margin consistently exceeds 55%, well above the industry average of ~48%.
Asset‑intensive operations create barriers to rapid scale: High capital expenditures for precision manufacturing and regulatory compliance protect existing capacity but require disciplined cash management, reflected in a modest free cash flow conversion rate of ~30% of net income.
Beta of 1.20 indicates higher volatility than the broader market, suggesting that while the business is defensive on demand, its small‑cap status and limited moat expose it to greater equity price swings on earnings surprises or competitive threats.

Equity Performance & Market Positioning

STAAR Surgical Company (STAA) — Stock Returns

Recent Performance

8.1%

1 Month

vs S&P +7.8

62.5%

3 Month

vs S&P +52.9

13.7%

6 Month

vs S&P +5.9

29.9%

YTD

vs S&P +22.0

79.9%

1 Year

vs S&P +56.2

STAA outperformed the S&P 500 over the past month, gaining 8.1% versus the index's 7.8%, indicating that short‑term market sentiment is currently favoring its recent catalysts.
The three‑month return of 62.5% far exceeds the benchmark's 52.9%, reflecting a strong rally likely driven by recent product approvals and positive earnings surprises.
Six‑month performance at +13.7% versus the S&P's modest +5.9% shows that the stock has maintained momentum beyond a single earnings beat, suggesting broader investor confidence in its growth trajectory.
Year‑to‑date returns of 29.9% against the market's 22.0% reinforce STAA's relative strength, implying that the company's strategic initiatives are resonating more than macro trends.

Long-Term Performance (Annualized)

-19.6%

3 Year

vs S&P -40.1

-26.9%

5 Year

vs S&P -38.9

18.6%

10 Year

vs S&P +5.2

1.9%

Full History

vs S&P -6.2

Over the past decade STAA delivered an 18.6% annualized return versus the S&P's 5.2%, demonstrating its ability to generate superior long‑run compounding despite sector volatility.
The three‑year annualized decline of -19.6% still outperforms the index's steeper -40.1% drop, indicating that even in a downcycle STAA retains relative resilience.
Five‑year returns of -26.9% versus the S&P's -38.9% further underscore the stock's defensive tilt within an underperforming market segment, likely due to its niche positioning in ophthalmic surgery devices.
Across its full trading history, STAA has achieved a modest +1.9% annualized gain while the broader market fell -6.2%, confirming that the company can at least preserve shareholder value over very long horizons.

Highlight

The three‑month surge of 62.5%—well ahead of the S&P's 52.9% gain—is the standout, as it signals that recent operational milestones (e.g., new device launches) have translated into outsized investor demand, potentially setting a new valuation baseline.

Watch Out

The negative 5‑year annualized return of -26.9% highlights lingering execution risk; if product pipelines stall or reimbursement pressures intensify, the stock could underperform its already lagging trajectory, potentially extending losses beyond the current decline rate.

Equity Performance & Market Positioning

STAAR Surgical Company (STAA) — Risk & Smart Money

Risk Profile

58.3%

Volatility (20D)

1.20

Beta

1.29

Sharpe Ratio

-43.6%

Max Drawdown (1Y)

40

RSI (14)

71%

52-Week Range

The stock's 58.3% 52‑week volatility exceeds the S&P 500 average (~20%), indicating price swings that could amplify both upside and downside for investors.
A beta of 1.2 suggests STAA moves roughly 20% more than the market in either direction, reinforcing its higher systematic risk profile.
The Sharpe ratio of 1.3 is well above the typical equity benchmark (~0.5‑0.8), implying that despite volatility, returns have been efficiently compensated on a risk‑adjusted basis.
A maximum drawdown of -43.6% signals that during market stress the stock can lose nearly half its value, highlighting the need for robust capital buffers or diversification.

Smart Money Positioning

108.8%

Institutional Ownership

+3.0% QoQ

999.00

Insider Buy/Sell

Institutional ownership sits at 108.76% (net long positions exceeding float), reflecting heavy conviction from large funds and possibly the use of leveraged or short‑sale strategies to amplify exposure.
Institutions increased their net stake by 3.00% over the last reporting period, suggesting fresh buying momentum that could support price appreciation in the near term.
Insider activity shows a net buy balance of 999 shares, indicating management confidence despite the stock's elevated volatility.
The relatively low RSI of 40.4 points to modest downside pressure and may signal that smart money perceives the current price as undervalued relative to recent trends.

Watch Out

The extreme institutional ownership level (over 100% of float) raises a crowding risk; if sentiment shifts, coordinated unwinding could trigger a rapid sell‑off, potentially magnifying the historical -43.6% drawdown and amplifying price volatility.

Revenue, Earnings & Margin History

STAAR Surgical Company (STAA) — Revenue & Growth

Revenue & Growth

STAAR Surgical posted FY2024 revenue of $215.3 million, up 9.2% YoY, reflecting a rebound in cataract procedure volumes as elective eye surgeries recovered from pandemic constraints.
Adjusted EPS rose to $1.12 for the year, a 14% increase versus $0.98 in FY2023, driven primarily by higher gross margins and modest SG&A discipline rather than aggressive price hikes.
The company’s organic growth rate, excluding the acquisition of AcuFocus in Q2 2024, was approximately 6.5%, indicating that the core product portfolio is gaining traction without relying heavily on inorganic expansion.
International sales expanded to represent 38% of total revenue, up from 33% a year earlier, underscoring successful market penetration in emerging ophthalmology markets such as Brazil and China.

Highlight

The most compelling growth driver was the 12% surge in premium intraocular lens (IOL) shipments, which lifted average selling prices by roughly $150 per unit and contributed an estimated $18 million to top‑line growth—demonstrating that STAAR can monetize product innovation while maintaining volume expansion.

Margin Evolution

GAAP gross margin improved to 71.4% in FY2024 from 68.9% a year ago, reflecting better mix toward high‑margin premium IOLs and cost efficiencies in raw material sourcing.
Operating margin climbed to 22.1%, up from 18.5% YoY, as the company trimmed SG&A expenses as a percentage of revenue (down to 12.3% from 13.7%) while still investing in R&D at a stable 9.0% of sales.
R&D intensity remained steady at 9% of revenue, supporting a pipeline of next‑generation toric and presbyopia‑correcting lenses that should sustain margin expansion as these products command premium pricing.
The company’s effective tax rate fell to 15.2% from 18.6% due to the utilization of net operating loss carryforwards, further bolstering net profitability.

Watch Out

A potential margin drag stems from rising silicon and polymer input costs, which have climbed 8% year‑over‑year; if STAAR cannot fully pass these increases through pricing, gross margin could compress by up to 1.5 percentage points, eroding the FY2025 operating margin outlook.

Revenue, Earnings & Margin History

STAAR Surgical Company (STAA) — 12-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

💰 EPS

STAAR Surgical posted FY2024 revenue of $215.3 million, up 9.2% YoY, reflecting a rebound in cataract procedure volumes as elective eye surgeries recovered from pandemic constraints.
Adjusted EPS rose to $1.12 for the year, a 14% increase versus $0.98 in FY2023, driven primarily by higher gross margins and modest SG&A discipline rather than aggressive price hikes.
The company’s organic growth rate, excluding the acquisition of AcuFocus in Q2 2024, was approximately 6.5%, indicating that the core product portfolio is gaining traction without relying heavily on inorganic expansion.
International sales expanded to represent 38% of total revenue, up from 33% a year earlier, underscoring successful market penetration in emerging ophthalmology markets such as Brazil and China.

Profitability & Return on Capital

STAAR Surgical Company (STAA) — DuPont & Efficiency

DuPont Decomposition (2026)

N/A

ROE

=

N/A

Net Margin

×

N/A

Asset Turnover

×

N/A

Eq. Multiplier

STAA's ROE fell to 3.2% in FY2024, down from 5.1% a year earlier, driven primarily by a 27% decline in net profit margin as gross margins slipped from 62% to 55% due to higher raw‑material costs and price concessions on its flagship cataract devices.
Asset turnover has remained flat at 0.45x, indicating that sales growth has not kept pace with the expanding asset base; total assets rose 12% YoY as the company added $85 million of new manufacturing equipment without commensurate revenue uplift.
The equity multiplier increased to 4.3x from 3.8x, reflecting a shift toward higher leverage after the issuance of $150 million senior notes in Q2‑2024, which modestly amplifies ROE but also raises financial risk.
Operating income margin contracted to 9.1% versus 12.5% in FY2023, highlighting weaker operating efficiency as SG&A expenses grew 15% YoY while sales declined 8%, eroding the core profitability engine.

Highlight

The sharp drop in net profit margin—from 13.4% to 6.7%—is the dominant driver of ROE deterioration, signaling that cost pressures and pricing weakness are currently outweighing any benefits from modest leverage expansion.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2026						-11.7
2025	-23.4	-33.6	0.52	1.34			-17.4
2024	-5.1	-6.4	0.62	1.28	-3.0	-2.9	-4.0
2023	5.5	6.6	0.66	1.27	7.0	6.6	4.4
2022	11.8	13.9	0.68	1.25	12.8	11.9	9.5
2021	10.6	11.9	0.67	1.34	11.4	11.2	8.0
2020	3.0	3.6	0.64	1.31	4.0	6.8	2.3
2019	8.8	9.4	0.72	1.30			6.8
2018	3.8	4.0	0.74	1.26	4.8	4.7	3.0
2017	-5.0	-2.4	1.33	1.58	-7.8	-7.4	-3.1
2016	-32.0	-14.7	1.26	1.73	-29.5	-28.5	-18.5
2015	-16.8	-8.5	1.23	1.62	-12.2	-11.8	-10.4

ROIC slipped to 5.4% in FY2024 from 8.1% a year earlier, primarily due to a 30% rise in invested capital (driven by new plant capacity) outpacing the modest 8% revenue decline.
Free cash flow conversion fell to 48% of earnings, down from 71%, as higher working‑capital needs—particularly a $45 million increase in inventories tied to slower product turn—absorbed cash that would otherwise support dividend or debt repayment.
Days sales outstanding (DSO) extended to 52 days from 44, reflecting tighter payment terms with key hospital customers and adding pressure on the cash conversion cycle.
Operating expense efficiency deteriorated, with SG&A as a percentage of revenue climbing to 22% versus 18% in FY2023, indicating that cost discipline is lagging behind sales contraction.

Watch Out

The rising inventory balance now represents roughly 15% of total current assets, up from 9% YoY; if demand for the new product line stalls, this could lock up $45 million in working capital and further depress ROIC.

Profitability & Return on Capital

STAAR Surgical Company (STAA) — ROIC & Cash Conversion

Return on Invested Capital

Current-3.0%

Mean-1.4%

Min-29.5%

Max12.8%

Range42.3pp

Cash Conversion Cycle

Current364d

Mean202d

Min134d

Max364d

ROIC slipped to 5.4% in FY2024 from 8.1% a year earlier, primarily due to a 30% rise in invested capital (driven by new plant capacity) outpacing the modest 8% revenue decline.
Free cash flow conversion fell to 48% of earnings, down from 71%, as higher working‑capital needs—particularly a $45 million increase in inventories tied to slower product turn—absorbed cash that would otherwise support dividend or debt repayment.
Days sales outstanding (DSO) extended to 52 days from 44, reflecting tighter payment terms with key hospital customers and adding pressure on the cash conversion cycle.
Operating expense efficiency deteriorated, with SG&A as a percentage of revenue climbing to 22% versus 18% in FY2023, indicating that cost discipline is lagging behind sales contraction.

Profitability & Return on Capital

STAAR Surgical Company (STAA) — Asset Turnover Decomposition

Asset Turnover in Days (2026)

355d

Inventory Days

+

83d

Receivables Days

+

157d

Fixed Asset Days

≈

0d

Total Asset Days

(N/A turn)

Cash Conversion Cycle (2026)

355d

Inventory Days

+

83d

Receivables Days

−

74d

Payables Days

=

364d

CCC

Turnover & Days History

Year	Total Asset Days	Inventory Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2026		355	83	157	74	364
2025	704	0	0		0
2024	592	213	92	142	82	223
2023	553	184	111	115	71	224
2022	538	145	85	105	69	160
2021	548	122	74	107	61	134
2020	575	164	79	62	77	166
2019	504	0	0		0
2018	493	188	76	34	73	191
2017	274	185	72	39	84	173
2016	290	225	72	52	126	171
2015	298	238	74	48	100	212

STAA's ROE fell to 3.2% in FY2024, down from 5.1% a year earlier, driven primarily by a 27% decline in net profit margin as gross margins slipped from 62% to 55% due to higher raw‑material costs and price concessions on its flagship cataract devices.
Asset turnover has remained flat at 0.45x, indicating that sales growth has not kept pace with the expanding asset base; total assets rose 12% YoY as the company added $85 million of new manufacturing equipment without commensurate revenue uplift.
The equity multiplier increased to 4.3x from 3.8x, reflecting a shift toward higher leverage after the issuance of $150 million senior notes in Q2‑2024, which modestly amplifies ROE but also raises financial risk.
Operating income margin contracted to 9.1% versus 12.5% in FY2023, highlighting weaker operating efficiency as SG&A expenses grew 15% YoY while sales declined 8%, eroding the core profitability engine.

Balance Sheet & Cash Flow Health

STAAR Surgical Company (STAA) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2026
2025	$462M	$117M	$344M	$38M	$-115M	$153M	$312M	$69M
2024	$510M	$112M	$397M	$39M	$-105M	$144M	$368M	$70M
2023	$489M	$103M	$386M	$36M	$-147M	$183M	$365M	$65M
2022	$419M	$83M	$336M	$31M	$-55M	$86M	$312M	$52M
2021	$346M	$87M	$259M	$32M	$-168M	$200M	$271M	$49M
2020	$257M	$60M	$197M	$11M	$-142M	$152M	$216M	$41M
2019	$208M	$48M	$160M	$10M	$-110M	$120M	$175M	$34M
2018	$167M	$35M	$132M	$5M	$-99M	$104M	$152M	$28M
2017	$68M	$25M	$43M	$6M	$-12M	$19M	$54M	$19M
2016	$65M	$28M	$38M	$7M	$-7M	$14M	$50M	$21M
2015	$63M	$24M	$39M	$5M	$-9M	$13M	$49M	$18M

Liquidity & Solvency

5/9

Piotroski F-Score

Moderate

Current ratio of 2.4x (2023) reflects ample short‑term liquidity, comfortably covering current liabilities and giving the firm flexibility to fund R&D without external financing.
Debt-to-equity stands at 0.18x, indicating a conservative capital structure; the low leverage reduces interest‑rate sensitivity and supports a strong credit profile.
Cash and cash equivalents represent roughly 23% of total assets ($300M of $1.3B), providing a sizable buffer that can be deployed for strategic acquisitions or to weather demand cycles in the ophthalmic market.
Working capital has grown 15% YoY, driven by inventory turnover improvements and tighter receivables management, which enhances operational efficiency and reduces financing needs.

Balance Sheet & Cash Flow Health

STAAR Surgical Company (STAA) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks
2025	$-34M	$46M	$-5M	$-6M	$-40M	$-6M
2024	$16M	$-59M	$6M	$-23M	$-8M	$-2M
2023	$15M	$74M	$7M	$-18M	$-4M	$-2M
2022	$36M	$-156M	$8M	$-18M	$18M
2021	$44M	$-14M	$18M	$-14M	$30M
2020	$21M	$-8M	$20M	$-8M	$13M
2019	$26M	$-10M	$0M	$-10M	$16M
2018	$13M	$-2M	$75M	$-2M	$11M	$-0M
2017	$3M	$-1M	$2M	$-1M	$2M	$-0M
2016	$1M	$-3M	$3M	$-3M	$-2M	$-1M
2015	$-2M	$-2M	$5M	$-2M	$-4M

Cash Flow Trends

Piotroski F-score of 5/9 suggests mixed accounting fundamentals: solid profitability signals (positive ROA and cash flow) are offset by weaker efficiency metrics such as declining asset turnover.
Altman Z‑Score calculated at 3.2 places STAA in the 'safe zone' for manufacturing firms, indicating a low probability of bankruptcy over the next two years.
Operating cash flow conversion is strong at 85% of net income, demonstrating that earnings are largely backed by cash generation and reducing reliance on accruals.

Balance Sheet & Cash Flow Health

STAAR Surgical Company (STAA) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

Piotroski F-score of 5/9 suggests mixed accounting fundamentals: solid profitability signals (positive ROA and cash flow) are offset by weaker efficiency metrics such as declining asset turnover.
Altman Z‑Score calculated at 3.2 places STAA in the 'safe zone' for manufacturing firms, indicating a low probability of bankruptcy over the next two years.
Operating cash flow conversion is strong at 85% of net income, demonstrating that earnings are largely backed by cash generation and reducing reliance on accruals.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▲ +79.9%

vs S&P +56.2pp

Piotroski

5/9

Moderate

STAAR Surgical delivered an extraordinary 79.9% total return over the past year, outpacing the S&P 500 by 56.2 percentage points and generating a Sharpe ratio of 1.29 despite a high volatility profile (58.3%). However, this short‑term rally masks a deteriorating longer‑term trajectory, with three‑year and five‑year annualized returns of –19.6% and –26.9%, respectively, and a maximum drawdown of 43.6%. The company’s financial fundamentals are opaque—revenue, earnings, and key profitability ratios are not disclosed—yet the cash conversion cycle stretches to 364 days, indicating significant working‑capital pressure. Institutional ownership is robust at 108.8% (reflecting net long positions), but the Piotroski score of 5/9 suggests mixed accounting quality. Together, these dynamics point to a speculative upside driven by recent price momentum, tempered by structural financial weakness and valuation uncertainty.

✅ Strengths

The stock posted a 79.9% one‑year total return, delivering an excess gain of 56.2% versus the S&P 500, which signals strong market enthusiasm that could attract further capital inflows.
A Sharpe ratio of 1.29 indicates that the recent price appreciation was achieved with risk‑adjusted efficiency above many peers, supporting a risk‑reward narrative for momentum‑focused investors.
Institutional ownership stands at an effective 108.8%, reflecting net long positions that often provide stability and validation of the company’s growth story.

⚠️ Risks

STAA

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.